Follow
Philip F Halloran
Philip F Halloran
Professor of Medicine, University of Alberta
Verified email at ualberta.ca - Homepage
Title
Cited by
Cited by
Year
The Banff 97 working classification of renal allograft pathology
LC Racusen, K Solez, RB Colvin, SM Bonsib, MC Castro, T Cavallo, ...
Kidney international 55 (2), 713-723, 1999
36351999
Banff 07 classification of renal allograft pathology: updates and future directions
K Solez, RB Colvin, LC Racusen, M Haas, B Sis, M Mengel, PF Halloran, ...
American journal of transplantation 8 (4), 753-760, 2008
21842008
Reduced exposure to calcineurin inhibitors in renal transplantation
H Ekberg, H Tedesco-Silva, A Demirbas, Š Vítko, B Nashan, A Gürkan, ...
New England Journal of Medicine 357 (25), 2562-2575, 2007
19392007
Immunosuppressive drugs for kidney transplantation
PF Halloran
New England Journal of Medicine 351 (26), 2715-2729, 2004
18272004
International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology
K Solez, RA Axelsen, H Benediktsson, JF Burdick, AH Cohen, RB Colvin, ...
Kidney international 44 (2), 411-422, 1993
16731993
Understanding the causes of kidney transplant failure: the dominant role of antibody‐mediated rejection and nonadherence
J Sellarés, DG De Freitas, M Mengel, J Reeve, G Einecke, B Sis, ...
American Journal of Transplantation 12 (2), 388-399, 2012
14252012
Banff'05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’)
K Solez, RB Colvin, LC Racusen, B Sis, PF Halloran, PE Birk, ...
American Journal of Transplantation 7 (3), 518-526, 2007
13142007
Antibody‐mediated rejection criteria–an addition to the Banff′ 97 classification of renal allograft rejection
LC Racusen, RB Colvin, K Solez, MJ Mihatsch, PF Halloran, ...
American Journal of Transplantation 3 (6), 708-714, 2003
12862003
Interleukin-2–receptor blockade with daclizumab to prevent acute rejection in renal transplantation
F Vincenti, R Kirkman, S Light, G Bumgardner, M Pescovitz, P Halloran, ...
New England Journal of Medicine 338 (3), 161-165, 1998
10241998
A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
P Keown, P Häyry, P Morris, C Stiller, C Barker, L Carr, D Landsberg, ...
Transplantation 61 (7), 1029-1037, 1996
9621996
Costimulation blockade with belatacept in renal transplantation
F Vincenti, C Larsen, A Durrbach, T Wekerle, B Nashan, G Blancho, ...
New England Journal of Medicine 353 (8), 770-781, 2005
9612005
Banff’09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups
B Sis, M Mengel, M Haas, RB Colvin, PF Halloran, LC Racusen, K Solez, ...
American journal of transplantation 10 (3), 464-471, 2010
8862010
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative …
M Haas, A Loupy, C Lefaucheur, C Roufosse, D Glotz, D Seron, ...
American Journal of Transplantation 18 (2), 293-307, 2018
7902018
Antibody‐mediated microcirculation injury is the major cause of late kidney transplant failure
G Einecke, B Sis, J Reeve, M Mengel, PM Campbell, LG Hidalgo, ...
American Journal of Transplantation 9 (11), 2520-2531, 2009
7272009
MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS: A Pooled Efficacy Analysis of Three Randomized, Double-Blind, Clinical Studies in Prevention of Rejection1
P Halloran, T Mathew, S Tomlanovich, C Groth, L Hooftman, C Barker
Transplantation 63 (1), 39-47, 1997
6901997
Rethinking chronic allograft nephropathy: the concept of accelerated senescence
PF Halloran, A Melk, C Barth
Journal of the American Society of Nephrology 10 (1), 167-181, 1999
5761999
Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure
RS Gaston, JM Cecka, BL Kasiske, AM Fieberg, R Leduc, FC Cosio, ...
Transplantation 90 (1), 68-74, 2010
5462010
Endothelial gene expression in kidney transplants with alloantibody indicates antibody‐mediated damage despite lack of C4d staining
B Sis, GS Jhangri, S Bunnag, K Allanach, B Kaplan, PF Halloran
American Journal of Transplantation 9 (10), 2312-2323, 2009
5072009
Banff 2011 Meeting report: new concepts in antibody‐mediated rejection
M Mengel, B Sis, M Haas, RB Colvin, PF Halloran, LC Racusen, K Solez, ...
American Journal of Transplantation 12 (3), 563-570, 2012
4832012
Delayed graft function in renal transplantation: etiology, management and long-term significance
DA Shoskes, PF Halloran
The Journal of urology 155 (6), 1831-1840, 1996
4161996
The system can't perform the operation now. Try again later.
Articles 1–20